SSRI Use in GPVI Deficiency: Relative Contraindication Requiring Careful Risk Assessment

Understanding the Dual Bleeding Risk

GPVI deficiency is a rare inherited platelet function disorder that impairs collagen-mediated platelet activation and thrombus formation under arterial shear conditions, typically presenting with mild to moderate bleeding diathesis in patients, according to the Journal of Thrombosis and Haemostasis 1, 2, 3

The American Academy of Child and Adolescent Psychiatry recommends monitoring for suicidal ideation in patients under 24, as they have an elevated risk, which is relevant for a 17-year-old patient with GPVI deficiency 4, 5

The minimum effective SSRI dose should be used, as bleeding risk is strongly dose-related, and consideration should be given to selecting SSRIs with lower sexual dysfunction profiles, according to Praxis Medical Insights 5
Establishing baseline bleeding severity and platelet function testing is necessary, as well as monitoring for new or worsening bleeding symptoms, particularly in patients with pre-existing platelet dysfunction like GPVI deficiency 1, 2, 3
Regular screening for suicidal ideation is required given the patient's age, and education on photosensitivity precautions is necessary, as recommended by Praxis Medical Insights 4, 5

Never combine SSRIs with MAOIs due to potentially fatal serotonin syndrome risk, and never abruptly discontinue SSRIs, as gradual taper is required to prevent withdrawal syndrome, according to Praxis Medical Insights 5